Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 …

WM Hackeng, LAA Brosens, JY Kim, R O'Sullivan… - Gut, 2022 - gut.bmj.com
Objective Recent studies have found aristaless-related homeobox gene (ARX)/pancreatic
and duodenal homeobox 1 (PDX1), alpha-thalassemia/mental retardation X-linked …

Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine …

AD Singhi, TC Liu, JL Roncaioli, D Cao, HJ Zeh… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: Pancreatic neuroendocrine tumors (PanNET) are a heterogeneous group
of neoplasms with increasing incidence and unpredictable behavior. Whole-exome …

Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival

JY Kim, JA Brosnan-Cashman, S An, SJ Kim… - Clinical Cancer …, 2017 - AACR
Purpose: Alternative lengthening of telomeres (ALT), a telomerase-independent telomere
maintenance mechanism, is strongly associated with ATRX and DAXX alterations and …

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors

I Marinoni, AS Kurrer, E Vassella, M Dettmer… - Gastroenterology, 2014 - Elsevier
Background & Aims Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and
genetically heterogeneous. Chromosome instability (CIN) has been detected in pNETs from …

ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors

A Chou, M Itchins, PR de Reuver, J Arena, A Clarkson… - Human pathology, 2018 - Elsevier
Pancreatic neuroendocrine tumors (PanNETs) are rare neoplasms accounting for 1% to 2%
of all pancreatic tumors. The biological behavior of PanNETs is heterogeneous and …

Alternative lengthening of telomeres and differential expression of endocrine transcription factors distinguish metastatic and non-metastatic insulinomas

WM Hackeng, W Schelhaas, FHM Morsink… - Endocrine …, 2020 - Springer
Insulin-producing pancreatic neuroendocrine tumors (PanNETs)/insulinomas are generally
considered to be indolent tumors with an excellent prognosis after complete resection …

[HTML][HTML] DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors

JK Park, WH Paik, K Lee, JK Ryu, SH Lee, YT Kim - Oncotarget, 2017 - ncbi.nlm.nih.gov
Background PanNETs shows heterogeneous biological behaviors. The aim was to
investigate prognostic markers based on most frequently mutated genes in PanNETs …

Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases

A Pea, J Yu, L Marchionni, M Noe, C Luchini… - Annals of …, 2020 - journals.lww.com
Objective: The aim of this study was to investigate the key molecular alterations in small
primary pancreatic neuroendocrine tumors (PanNETs) associated with the development of …

Loss of chromatin-remodeling proteins and/or CDKN2A associates with metastasis of pancreatic neuroendocrine tumors and reduced patient survival times

S Roy, WA LaFramboise, TC Liu, D Cao, A Luvison… - Gastroenterology, 2018 - Elsevier
Despite prognostic grading and staging systems, it is a challenge to predict outcomes for
patients with pancreatic neuroendocrine tumors (PanNETs). Sequencing studies of …

Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 …

RF De Wilde, CM Heaphy, A Maitra, AK Meeker… - Modern …, 2012 - nature.com
Approximately 45% of sporadic well-differentiated pancreatic neuroendocrine tumors harbor
mutations in either ATRX (alpha thalassemia/mental retardation X-linked) or DAXX (death …